GlassScriptPhysician profile
Serazul Khan
NPI 1073502019
$2,504.31
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,928 · 2020: $512 · 2021: $24.75 · 2023: $39.50.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $39.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $39.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $361.76 | 2019-2020 | |
| Lexicon Pharmaceuticals, INC. | $251.75 | 2019 | |
| Genentech USA, INC. | $214.52 | 2019-2020 | |
| Pfizer INC. | $181.87 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $177.78 | 2019-2020 | |
| Amgen INC. | $169.17 | 2019-2020 | |
| Celgene Corporation | $163.06 | 2019-2020 | |
| Seagen INC. | $141.48 | 2019 | |
| Eisai INC. | $96.19 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.32 | 2019-2020 | |
| Emd Serono, INC. | $69.12 | 2019-2020 | |
| Clovis Oncology, INC. | $59.86 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $57.89 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $56.97 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $46.98 | 2019-2020 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $46.67 | 2019 | |
| Eagle Pharmaceuticals, INC. | $39.50 | 2023 | |
| Rigel Pharmaceuticals, INC. | $36.95 | 2020 | |
| Genzyme Corporation | $36.21 | 2019 | |
| Csl Behring | $30.77 | 2019 | |
| Lilly USA, LLC | $23.74 | 2019 | |
| Janssen Pharmaceuticals, INC | $20.19 | 2019 | |
| Jazz Pharmaceuticals INC. | $18.41 | 2019 | |
| Partner Therapeutics, INC. | $16.84 | 2019 | |
| Sun Pharmaceutical Industries INC. | $15.99 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.95 | 2020 | |
| Array Biopharma INC | $13.00 | 2021 | |
| Incyte Corporation | $12.76 | 2019 | |
| Astellas Pharma US INC | $12.36 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $11.85 | 2019 | |
| Kite Pharma, INC. | $11.75 | 2021 | |
| Verastem, INC. | $11.42 | 2019 | |
| Exelixis INC. | $11.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Serazul Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.